To secure long-term innovation, Ascendis Pharma's Ivanna Rosendal suggests pharma companies should help startup companies through their growing pains.
- How To Lead A Moonshot Collaboration: Lessons From Over A Decade Of Competitors Working Together
- Patient Trust In Pharma Is Low; Here's How To Rebuild It
- Why Dr. Robert Califf Isn't Pulling His Punches Anymore
- The U.S. Trial Advantage Is Eroding
- Making AI Safety Routine: How Sites And Sponsors Can Continuously Monitor Clinical AI
- Want To Optimize Clinical Project Team Performance? Try This Formal 'Lessons Learned' Process
- 4 Factors Changing The Way CRAs Monitor Trials
GUEST COLUMNISTS
-
Want To Optimize Clinical Project Team Performance? Try This Formal 'Lessons Learned' Process
Learn how a formal "lessons learned" process can help teams work collaboratively with open, honest, and timely communication to reach thoughtful decisions that lead to on-time, on-budget, and inspection-ready trials.
-
4 Factors Changing The Way CRAs Monitor Trials
The way CRAs monitor is about to change. Regeneron's Patrick Floody discusses these four factors that will influence it.
-
How Can AI Change Computerized System Validation?
Learn how AI technologies are changing the computer system validation (CSV) landscape and what you need to understand about this transformation.
-
Too Little Info, Too Much Time Wasted: Feasibility Challenges For Sites
Incomplete protocols, lengthy sponsor decision timelines, and uncompensated work plague clinical research sites. Learn why these issues exist and how to address them alongside experts from SCRS and Tufts CSDD.
-
Will New AI Health Assistants Suggest Clinical Trials To Inquiring Patients?
New AI health assistants are now doing even more to help patients make sense of symptoms, diagnoses, and treatment options. What does that mean for the discoverability of clinical trials?
-
What CROs Do Right Isn't Always Obvious To Research Sites
CROs are doing many things right. But it's when that right thing is understood — not just executed — that the impact becomes far greater than compliance alone.
-
How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials
VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.
-
3 Clinical Research Attorneys Talk 2026 Trends
Three life sciences legal experts share what they see happening in the year ahead — and what should remain firmly in the past.
CLINICAL TRIAL WHITE PAPERS
-
Closing The Gap In Our Understanding Of Sleep Health With DHTs
What is the current state of sleep assessments in clinical trials, regulatory expectations, and what opportunities do wearable digital health technologies present?
-
Wearables For Optical Cardiovascular Monitoring6/10/2025
Wearable digital health technologies (DHTs) are transforming cardiovascular health monitoring by enabling continuous, real-world assessment through optical sensors like photoplethysmography (PPG).
-
Deal-Making Volume Slowed In 20235/15/2024
This report provides an overview of alliance, merger and acquisition, and financing deal activities across the global biopharma, medical device, and in vitro diagnostics industries in 2023, as reported by Biomedtracker.
-
Study Start-Up Challenges: Hard Realities, Effective Strategies3/13/2024
Launching a study is complex, and the time between protocol approval and the first patient visit has increased dramatically. How can companies reverse this trend and accelerate study start-ups?
-
Radiopharmaceutical Therapy: Global Clinical Trial Insights 20247/3/2024
By downloading this report, readers will uncover the transformative potential of radiopharmaceuticals in cancer therapy and stay ahead in the evolving cancer treatment landscape.
-
Diffuse Large B-Cell Lymphoma- Global Clinical Trial Landscape10/15/2024
Explore the latest advancements in diffuse large B-cell lymphoma research, innovative therapies, and personalized care strategies shaping the future of treatment.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Muscular Dystrophy: Multi-National And Multi-Site Trials10/15/2024
Learn about the success ReveraGen found when expanding their partnership with Novotech to a larger phase 2b trial (VBP15-004) in Duchenne Muscular Dystrophy (DMD).
-
GxP Inventory Solution Delivers Real-Time Visibility, Operational Efficiency12/10/2025
Explore how unified forecasting and GxP-level inventory control can streamline your clinical supply chain, reduce risk, and strengthen oversight across every trial you run.
-
Accelerating Early Phase Oncology Study Development4/17/2025
Explore a close collaboration to co-develop a comprehensive, adaptive protocol designed to support key decisions across multiple trial phases for an innovative cancer therapy.
-
Pay-By-Procedure Vs. Pay-By-Visit12/8/2025
Explore how a pay-by-procedure model can reshape site payments, enhance transparency, and reveal meaningful efficiencies across complex clinical trials.
-
Analyzing 1,000+ Study Startup Records For Recruitment Performance5/17/2024
This overview highlights real research programs at various stages of the recruitment process and demonstrates the impact of Advarra’s Longboat Platform across multiple therapeutic areas and sponsors.
-
Streamlining Phase 1 Trials With The Mobile Vision Pod1/29/2025
A contract research organization formed a partnership to address significant challenges during a Phase 1 clinical trial for a corneal disease treatment through the use of a Mobile Vision Pod.
NEWSLETTER ARCHIVE
- 02.06.26 -- 4 Factors Changing The Way CRAs Monitor Trials
- 02.06.26 -- Pave The Way To Clinical Trial Operation Success
- 02.05.26 -- What To Watch For In The 2026 Clinical Trial Landscape
- 02.04.26 -- Is Your Team Burnt Out? Discover The ROI Of Healthy Employees Running Trials
- 02.04.26 -- STREAM Edition: Data Cleaning And Site Performance
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.
-
CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.
-
Once the go-to location for trials, the U.S. is now seeing competition from APAC, driven by political, economic, and workforce pressures domestically and rapid growth abroad.
FOCUS ON PATIENTS
-
The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.
-
CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.
-
VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.